Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...221222223224225226227228229230231...10661067»
  • ||||||||||  Is VTD the Best First Line Therapy for Multiple Myeloma in an Environment with Limited Resources? an Analysis of Outcomes and Costs. () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1201;    
    Patients with MM treated between 2017 and 2019 with 4 cycles of VTD (Bortezomib, thalidomide, dexamethasone) followed by auto-HSCT and maintenance with thalidomide were included...Conditioning was melphalan 200 mg/m2 in n=35 (79.5%)...Table 1 compares the costs of 4 induction cycles with usual scheme CONCLUSIONS The response with VTD followed by auto-HSCT and maintenance with thalidomide are comparable in overall and progression-free survival with more expensive schemes such as KRd, VRd and Dara-VTd with lower cost. Key words: stem cell trasplantation, multiple myeloma, cost, limited resource
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Impact of Age, Race, BMI, and Cytogenetics on Outcomes after Upfront Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1195;    
    Introduction: The combination of lenalidomide, bortezomib, and dexamethasone (RVd) followed by high dose therapy (HDT), autologous stem cell transplant (ASCT), and maintenance chemotherapy has become a standard of care for patients with transplant eligible newly diagnosed multiple myeloma (NDMM). RVd induction chemotherapy followed by HDT-ASCT and maintenance chemotherapy is associated with long-term PFS and OS, regardless of age, race, BMI, or cytogenetic risk profile.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab Based Induction Therapy - a Real World Experience () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1186;    
    Conclusion The addition of daratumumab to induction regimen of RVd did not lead to any clinically significant differences in stem cell yield and number of collection days, provided patient received pre-emptive GCSF and plerixafor. Patients with suboptimal collection on day one were able to collect adequate stem cells with additional doses of plerixafor with or without GCSF.
  • ||||||||||  cyclophosphamide / Generic mfg.
    Haploidentical Transplantation in Severe Thalassemia Patients Using Pre-Transplant Immunosuppression (PTIS) and Post-Transplant Cyclophosphamide () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1021;    
    -host disease (GvHD) prophylaxis with cyclophosphamide, tacrolimus or sirolimus, and short course mycophenolate mofetil...Conclusion We conclude that this is a safe and efficacious approach to allo-SCT in thalassemia patients with haploidentical donors. For the patients older than 18 years with very high anti DSA-titers, (MFI > 5,000), we have modified the PTIS by adding more bortezomib and rituximab and the conditioning regimen by adding thiotepa to further decrease the risk of graft rejection
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Improved Overall Survival in Patients with Acute GvHD with Ruxolitinib - a Single Center Experience () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1002;    
    Before Ruxolitinib became available for aGVHD therapy, patients with steroid-refractory aGVHD (SR-aGVHD) were treated with thymoglobuline, high dose dexamethasone, etanercept, and/or extracorporeal photopheresis (ECP)...Overall survival at 2 years after aGVHD was 53% (95% CI 45%-64%) and 64% (95% CI 57%-75%), respectively (P=0.04). A clinically meaningful improvement in the overall survival of patients with acute GVHD was observed after the introduction of ruxolitinib into clinical praxis.
  • ||||||||||  Kineret (anakinra) / SOBI
    Evaluation of Anakinra Use for CAR T-Cell Related Toxicities () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_880;    
    This study suggests that our patient population may benefit from the early use of anakinra in CAR T-cell therapy related neurotoxicity refractory to corticosteroids, or upfront in combination with dexamethasone in patients with initial Grade 3 or higher neurotoxicity. Future studies may be warranted to assess if the use of anakinra is significantly better when compared to those patients who do not receive it for ICANS management.
  • ||||||||||  cyclophosphamide / Generic mfg.
    Anaphylaxis to Cyclophosphamide Metabolites during Lymphodepletion for CAR-T Therapy () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_819;    
    Case description: A 13 year old boy was diagnosed with very high risk ALL in 2015 and had 2 isolated CNS relapses treated with intensified chemotherapy (chemo) and cranial radiation (1 st relapse) and Blinatumomab with intrathecal (IT) chemo followed by sibling donor HSCT (2 nd relapse)...Later, during lymphodepletion with fludarabine (Flu) and Cy, physiologic replacement hydrocortisone (HC) was briefly held to prevent interference with CAR-T function...CAR-T infusion was subsequently delayed by skin GVHD requiring glucocorticoids and COVID-19 infection treated with convalescent plasma and nirmatrelvir/ritonavir...Onset of anaphylaxis within hours rather than minutes after Cy administration supports hypersensitivity to Cy metabolites rather than to the drug itself. This case highlights the importance of consideration of sensitivity to Cy metabolites as well as acquired donor-specific allergy even when alternative explanations are likely.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Preclinical, Journal:  Effect of triamcinolone acetonide on retinal inflammation and angiogenesis induced by pericyte depletion in mouse. (Pubmed Central) -  Dec 16, 2022   
    These results suggested that TA improved inflammatory retinal events which were induced in pericyte-deleted mice by mainly decreasing macrophage-derived VEGF and expression of inflammatory cytokines followed by attenuation of vascular permeability and proliferation/migration of endothelial cells. Furthermore, in these processes, translocation of glucocorticoid receptor (GR) was partially involved.
  • ||||||||||  prednisolone / Generic mfg.
    Journal:  Severe alveolar bone resorption in Felty syndrome: a case report. (Pubmed Central) -  Dec 16, 2022   
    If their susceptibility to infection and pancytopenia-related bleeding can be managed, such patients can still receive comprehensive dental treatment, including teeth extractions and periodontal therapy. Cooperation among the dentist, hematologist, and patient is necessary to improve treatment outcomes and the patient's quality of life.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche, Rituxan (rituximab) / Roche
    Trial completion date, Trial primary completion date, Combination therapy:  Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (clinicaltrials.gov) -  Dec 16, 2022   
    P2,  N=49, Recruiting, 
    Combined phacoemulsification with intravitreal injections of ranibizumab or subtenon triamcinolone acetonide may prevent further progression in CMT in individuals with DME following cataract operation. Trial completion date: Dec 2022 --> Nov 2023 | Trial primary completion date: Dec 2022 --> Nov 2023
  • ||||||||||  bortezomib / Generic mfg., lenalidomide / Generic mfg.
    Enrollment change, Trial primary completion date:  PRISM: DARA RVD For High Risk SMM (clinicaltrials.gov) -  Dec 16, 2022   
    P2,  N=60, Recruiting, 
    Trial completion date: Dec 2022 --> Nov 2023 | Trial primary completion date: Dec 2022 --> Nov 2023 N=30 --> 60 | Trial primary completion date: Feb 2023 --> Feb 2026
  • ||||||||||  dexamethasone / Generic mfg.
    Enrollment change, Trial completion date, Trial termination:  Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy (clinicaltrials.gov) -  Dec 16, 2022   
    P1/2,  N=2, Terminated, 
    N=30 --> 60 | Trial primary completion date: Feb 2023 --> Feb 2026 N=39 --> 2 | Trial completion date: Jan 2025 --> Dec 2022 | Recruiting --> Terminated
  • ||||||||||  dexamethasone injection / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  The Effect of IV NSAID's and Corticosteroids on Dysphasia and Dysphonia Following ASDF (clinicaltrials.gov) -  Dec 16, 2022   
    P3,  N=75, Recruiting, 
    N=39 --> 2 | Trial completion date: Jan 2025 --> Dec 2022 | Recruiting --> Terminated Not yet recruiting --> Recruiting | Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Jan 2022 --> Jan 2024
  • ||||||||||  Empliciti (elotuzumab) / AbbVie, BMS
    Elotuzumab, Pomalidomide and Dexamethasone Maintenance after Salvage Second Autologous Transplant for Multiple Myeloma (World Center Marriott Magnolia 16-18; In-Person) -  Dec 15, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1179;    
    P2
    The median PFS of 29 months compares favorably to the median PFS of 14 months observed in our retrospective analysis of lenalidomide maintenance-exposed patients receiving 2 nd ASCT (Manjappa, BMT 2018). The future of 2 nd ASCT for relapsed MM remains unclear with the emergence of novel immunotherapies and future studies are needed.
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    Characteristics and history of care preceding the initiation in France of Fluticasone Furoate/Umeclidinium/Vilanderol (FF/Umec/VI) (Endoume 4) -  Dec 14, 2022 - Abstract #CPLF2023CPLF_966;    
    Conclusion These first real life data in French patients initiating a FF/UMEC/VI fixed triple therapy seem to indicate that this prescription mainly concerns severe and exacerbating COPD patients. The inhaled therapeutic load preceding this initiation appears identical according to the prescriber and seems consistent with the indication of Trelegy.
  • ||||||||||  dexamethasone / Generic mfg.
    Corticosteroids in the treatment of pneumonia in COVID-19: is a high dose reduces mortality? (Display area) -  Dec 14, 2022 - Abstract #CPLF2023CPLF_725;    
    Two groups were defined: group 1 (n = 169) having received 6 mg of dexamethasone; Group 2 (n = 64) having received more than 6 mg of dexamethasone...Conclusion A large dose of corticosteroids does not provide additional benefit in COVVI-19 pneumonia in terms of mortality, hospitalization duration and transfer to intensive care unit. More studies with a wider workforce are necessary to confirm these facts.
  • ||||||||||  dexamethasone / Generic mfg.
    Self-antibods neutralizing type I interferons and idiopathic pulmonary fibrosis (GOUDE 2) -  Dec 14, 2022 - Abstract #CPLF2023CPLF_476;    
    He received treatment with high speed oxygen therapy and dexamethasone for ten days allowing a return home...Conclusion This study does not suggest any association between FPI and anti-IC-IS type I, whether positive or negative. The presence of these ACs in three patients in our cohort was not associated with any particular characteristic at the time of diagnosis or monitoring.